<a href="https://laohu8.com/S/SRDX">SurModics</a> Inc. Reports Q3 FY 2025 Revenue Decrease of 3%, GAAP Loss Narrows to $5.3 Million; Adjusted EBITDA Rises to $3.4 Million
SurModics Inc., a provider of medical device and in vitro diagnostic technologies, announced financial results for the third quarter of fiscal year 2025, which ended on June 30, 2025. The company reported a total revenue of $29.6 million, marking a 3% decrease compared to the same period in the previous year. However, when excluding the _SurVeil™_ drug-coated balloon license fee revenue, the company noted a 1% year-over-year increase in total revenue. The GAAP net loss was reported at $5.3 million, an improvement from the $7.6 million loss in the previous year. Adjusted EBITDA showed positive movement, increasing to $3.4 million from $1.6 million in the third quarter of fiscal 2024. SurModics also updated its fiscal year 2025 financial guidance, raising its total revenue expectations to a range of $116.5 million to $118.5 million, reflecting a 6% to 8% decrease compared to fiscal 2024. Excluding _SurVeil_ DCB license fee revenue, the expected total revenue is projected to be between $115.0 million and $117.0 million, indicating a more moderate decrease of 3% to 5% compared to the prior fiscal year. The company continues to work towards completing the pending acquisition by an affiliate of GTCR, despite challenges presented by an FTC administrative complaint and federal court action.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SurModics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250808873337) on August 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.